{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:02:08Z","timestamp":1788454928196,"version":"build-2803163510"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022606","name":"Almirall","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"Background<\/jats:title>Vestibular side effects such as dizziness and vertigo can be a limitation for some antibiotics commonly used to treat acne, rosacea, and other dermatology indications.<\/jats:p><\/jats:sec>Objective<\/jats:title>Unlike minocycline, which is a second-generation tetracycline, sarecycline, a narrow-spectrum third-generation tetracycline-class agent approved to treat acne vulgaris, has demonstrated low rates of vestibular-related adverse events in clinical trials. In this work, we evaluate the brain-penetrative and lipophilic attributes of sarecycline in 2 non-clinical studies and discuss potential associations with vestibular adverse events.<\/jats:p><\/jats:sec>Methods<\/jats:title>Rats received either intravenous sarecycline or minocycline (1.0 mg\/kg). Blood-brain penetrance was measured at 1, 3, and 6 h postdosing. In another analysis, the lipophilicity of sarecycline, minocycline, and doxycycline was measured via<\/jats:italic> octanol\/water and chloroform\/water distribution coefficients (logD) at pH 3.5, 5.5, and 7.4.<\/jats:p><\/jats:sec>Results<\/jats:title>Unlike minocycline, sarecycline was not detected in brain samples postdosing. In the octanol\/water solvent system, sarecycline had a numerically lower lipophilicity profile than minocycline and doxycycline at pH 5.5 and 7.4.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>The reduced blood-brain penetrance and lipophilicity of sarecycline compared with other tetracyclines may explain low rates of vestibular-related adverse events seen in clinical trials.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.1033980","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T13:19:40Z","timestamp":1670505580000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Reduced blood-brain barrier penetration of acne vulgaris antibiotic sarecycline compared to minocycline corresponds with lower lipophilicity"],"prefix":"10.3389","volume":"9","author":[{"given":"Ayman","family":"Grada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Q.","family":"Del Rosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Y.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Stein Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Damiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Obagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raidah J.","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Ken","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Bunick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris.","volume":"74","author":"Zaenglein","year":"2016","journal-title":"J Am Acad Dermatol."},{"key":"B2","first-page":"19","article-title":"Oral doxycycline in the management of acne vulgaris: current perspectives on clinical use and recent findings with a new double-scored small tablet formulation.","volume":"8","author":"Del Rosso","year":"2015","journal-title":"J Clin Aesthet Dermatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/der2.49","article-title":"Treating acne with the tetracycline class of antibiotics: a review.","volume":"2","author":"Graber","year":"2021","journal-title":"Dermatol Rev."},{"key":"B4","year":"2011","journal-title":"SOLODYN [package insert]."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/jps.2600581003","article-title":"pH-Partition behavior of tetracyclines.","volume":"58","author":"Colaizzi","year":"1969","journal-title":"J Pharm Sci."},{"key":"B6","year":"2020","journal-title":"SEYSARA [package insert]."},{"key":"B7","first-page":"634","article-title":"Management of truncal acne with oral sarecycline: pooled results from two phase-3 clinical trials.","volume":"20","author":"Del Rosso","year":"2021","journal-title":"J Drugs Dermatol."},{"key":"B8","first-page":"987","article-title":"Once-daily oral sarecycline 1.5 mg\/kg\/day is effective for moderate to severe acne vulgaris: results from two identically designed, phase 3, randomized, double-blind clinical trials.","volume":"17","author":"Moore","year":"2018","journal-title":"J Drugs Dermatol."},{"key":"B9","first-page":"E53","article-title":"Safety and tolerability of sarecycline for the treatment of acne vulgaris: results from a phase III, multicenter, open-label study and a phase I phototoxicity study.","volume":"12","author":"Pariser","year":"2019","journal-title":"J Clin Aesthet Dermatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2147\/CCID.S190473","article-title":"Sarecycline: a review of preclinical and clinical evidence.","volume":"13","author":"Moore","year":"2020","journal-title":"Clin Cosmet Investig Dermatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/jps.2600800619","article-title":"Partitioning of solutes in different solvent systems: the contribution of hydrogen-bonding capacity and polarity.","volume":"80","author":"el Tayar","year":"1991","journal-title":"J Pharm Sci."},{"key":"B12","first-page":"11","article-title":"Dose-ranging efficacy of new once-daily extended-release minocycline for acne vulgaris.","volume":"78","author":"Stewart","year":"2006","journal-title":"Cutis."},{"key":"B13","first-page":"21","article-title":"Safety and efficacy of a new extended-release formulation of minocycline.","volume":"78","author":"Fleischer","year":"2006","journal-title":"Cutis."},{"key":"B14","first-page":"s6","article-title":"Oral tetracyclines and acne: a systematic review for dermatologists.","volume":"19","author":"Armstrong","year":"2020","journal-title":"J Drugs Dermatol JDD."},{"key":"B15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10096-017-3081-x","article-title":"Similarities and differences between doxycycline and minocycline: clinical and antimicrobial stewardship considerations.","volume":"37","author":"Cunha","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1128\/AAC.8.6.713","article-title":"Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in dogs.","volume":"8","author":"Barza","year":"1975","journal-title":"Antimicrob Agents Chemother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.12788\/cutis.0057","article-title":"Fighting acne for the fighting forces.","volume":"106","author":"Brahe","year":"2020","journal-title":"Cutis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/0090-4295(90)80201-W","article-title":"Tetracyclines in urology: current concepts.","volume":"36","author":"Cunha","year":"1990","journal-title":"Urology."},{"key":"B19","first-page":"40","article-title":"Oral antibiotic therapy for acne vulgaris: pharmacokinetic and pharmacodynamic perspectives.","volume":"4","author":"Leyden","year":"2011","journal-title":"J Clin Aesthet Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1002\/jps.21244","article-title":"Alternative measures of lipophilicity: from octanol-water partitioning to IAM retention.","volume":"97","author":"Giaginis","year":"2008","journal-title":"J Pharm Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"20530","DOI":"10.1073\/pnas.2008671117","article-title":"Sarecycline interferes with tRNA accommodation and tethers mRNA to the 70S ribosome.","volume":"117","author":"Batool","year":"2020","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B22","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1515\/hsz-2013-0292","article-title":"Tetracycline antibiotics and resistance mechanisms.","volume":"395","author":"Nguyen","year":"2014","journal-title":"Biol Chem."},{"key":"B23","doi-asserted-by":"publisher","first-page":"p. 105","DOI":"10.1016\/B978-0-12-384935-9.10006-9","article-title":"Chapter 6: Brain delivery of peptides and proteins.","author":"Duf\u00e8s","year":"2011","journal-title":"Peptide and Protein Delivery."},{"key":"B24","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1023\/A:1018969222130","article-title":"Hydrogen bonding potential as a determinant of the in vitro and in situ blood-brain barrier permeability of peptides.","volume":"11","author":"Chikhale","year":"1994","journal-title":"Pharm Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/3407091","article-title":"Determination of the lipophilicity of ibuprofen, naproxen, ketoprofen, and flurbiprofen with thin-layer chromatography.","volume":"2019","author":"Czyrski","year":"2019","journal-title":"J Chem."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10040439","article-title":"Antibacterial mechanisms and efficacy of sarecycline in animal models of infection and inflammation.","volume":"10","author":"Bunick","year":"2021","journal-title":"Antibiotics (Basel)."},{"key":"B27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2165\/00003495-197509040-00005","article-title":"Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use.","volume":"9","author":"Brogden","year":"1975","journal-title":"Drugs."},{"key":"B28","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/bph.12139","article-title":"Minocycline: far beyond an antibiotic.","volume":"169","author":"Zarzuelo","year":"2013","journal-title":"Br J Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1046\/j.1525-1470.1999.00106.x","article-title":"Complications of minocycline therapy for acne vulgaris: case reports and review of the literature.","volume":"16","author":"Somech","year":"1999","journal-title":"Pediatric Dermatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2165\/11319280-000000000-00000","article-title":"Minocycline in acne vulgaris.","volume":"11","author":"Ochsendorf","year":"2010","journal-title":"Am J Clin Dermatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1033980\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T13:19:48Z","timestamp":1670505588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1033980\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":30,"alternative-id":["10.3389\/fmed.2022.1033980"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.1033980","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,8]]},"article-number":"1033980"}}